All In Biotech

Drug Trial Radar · NCT03512756

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Participants With Metastatic Pancreatic Cancer

A Randomized Phase 2/3 Multi-Center Study of SM-88 in Subjects With Pancreatic Cancer Whose Disease Has Progressed or Recurred

Last checked: Nov 20, 2026Latest source record: Nov 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 130 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

130

Actual

Start

Mar 27, 2018

Primary completion

Dec 28, 2021

Study completion Dec 28, 2021

Sponsor

Lead sponsor
Tyme, IncIndustry
Sponsor type
Industry
First posted
May 1, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A prospective, open-label phase 2/3 trial in metastatic pancreatic cancer participants who have failed two lines of prior systemic therapy. The trial is designed to evaluate the safety and efficacy of SM-88 used with MPS (methoxsalen, phenytoin and sirolimus) in pancreatic cancer and will measure multiple endpoints, including overall survival, progression free survival, relevant biomarkers, quality of life, safety, and overall response rate. (Part 1 enrollment complete) In the initial stage of the trial (36 participants), two dose levels of SM-88's metyrosine-derivative was evaluated. (Part 2 actively enrolling) The second part will consist of a subsequent expansion of the trial to further assess safety and efficacy of SM-88 used with MPS containing the selected SM-88 RP2D from Part 1. A total of 250 participants in the second part will be randomized 1:1 either to the SM-88 arm (125 participants) or Physician's Choice of therapy for the Control Arm (125 participants). Participants should have previously received two lines of prior systemic therapy.

Conditions

  • Pancreatic Cancer

Interventions

  • SM-88 used with MPS (methoxsalen, phenytoin, sirolimus)Drug

    Daily oral therapy for cancer

  • Capecitabine, Gemcitabine, and 5-FUDrug

    Investigator choice of the following therapies: Capecitabine, Gemcitabine, and 5-FU

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: Up to 12 months

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • City Of Hope

    Duarte, California

  • Sarcoma Oncology Research Center

    Santa Monica, California

  • Hartford Healthcare Cancer

    New Britain, Connecticut

  • H. Lee Moffitt Cancer Center & Research Institute

    Tampa, Florida

  • Advent Health Florida Hospital Tampa

    Tampa, Florida

  • June E. Nylen Cancer Center

    Sioux City, Iowa

  • University Medical Center

    New Orleans, Louisiana

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Washington University

    St Louis, Missouri

  • North Shore Hematology Oncology

    East Setauket, New York

  • NY Cancer and Blood Specialist

    East Setauket, New York

  • NYU Langone Health

    New York, New York

  • Central Park Hematology & Oncology

    New York, New York

  • Weill Cornell

    New York, New York

  • New York Cancer and Blood Specialist

    The Bronx, New York

  • The Ohio State University

    Columbus, Ohio

  • Texas Oncology-Baylor

    Dallas, Texas

  • MD Anderson

    Houston, Texas

  • Virginia Mason Medical Center

    Seattle, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.